KR20250009417A - 혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도 - Google Patents

혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도 Download PDF

Info

Publication number
KR20250009417A
KR20250009417A KR1020247034049A KR20247034049A KR20250009417A KR 20250009417 A KR20250009417 A KR 20250009417A KR 1020247034049 A KR1020247034049 A KR 1020247034049A KR 20247034049 A KR20247034049 A KR 20247034049A KR 20250009417 A KR20250009417 A KR 20250009417A
Authority
KR
South Korea
Prior art keywords
compound
formula
mouse
body weight
mpk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034049A
Other languages
English (en)
Korean (ko)
Inventor
파보드 샤오제이
셰 팡
제이. 에드워드 셈플
미레유 길링스
Original Assignee
후야바이오 인터내셔널, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후야바이오 인터내셔널, 엘엘씨 filed Critical 후야바이오 인터내셔널, 엘엘씨
Publication of KR20250009417A publication Critical patent/KR20250009417A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247034049A 2022-03-14 2023-03-10 혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도 Pending KR20250009417A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263319589P 2022-03-14 2022-03-14
US63/319,589 2022-03-14
PCT/US2023/015021 WO2023177592A1 (en) 2022-03-14 2023-03-10 Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof

Publications (1)

Publication Number Publication Date
KR20250009417A true KR20250009417A (ko) 2025-01-17

Family

ID=88024124

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034049A Pending KR20250009417A (ko) 2022-03-14 2023-03-10 혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도

Country Status (7)

Country Link
US (1) US20230293539A1 (https=)
EP (1) EP4493184A4 (https=)
JP (1) JP2025509830A (https=)
KR (1) KR20250009417A (https=)
CA (1) CA3245866A1 (https=)
MX (1) MX2024011346A (https=)
WO (1) WO2023177592A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090881A1 (en) * 2023-10-27 2025-05-01 Huyabio International, Llc Combination therapies of wdr5 inhibitors and pd-1 inhibitors
WO2026058961A1 (en) 2024-09-13 2026-03-19 Alivexis, Inc. Wdr5 inhibitors, compounds, pharmaceutical compositions, and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063058B2 (en) * 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US11319299B2 (en) * 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
CN107382840B (zh) * 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
WO2019046944A1 (en) * 2017-09-06 2019-03-14 Propellon Therapeutics Inc. INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN
CN108715585A (zh) * 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
EP4523755A3 (en) * 2018-09-18 2025-06-11 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents
CN109734674B (zh) * 2019-02-26 2022-08-26 中国药科大学 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
TWI899080B (zh) * 2019-05-27 2025-10-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑

Also Published As

Publication number Publication date
CA3245866A1 (en) 2023-09-21
WO2023177592A1 (en) 2023-09-21
MX2024011346A (es) 2025-01-09
JP2025509830A (ja) 2025-04-11
EP4493184A1 (en) 2025-01-22
EP4493184A4 (en) 2026-03-18
US20230293539A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US10568884B2 (en) Compounds and compositions as protein kinase inhibitors
EP3584239B1 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
EP3196197A1 (en) Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor
EP3677584A1 (en) Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity
EP3828178A1 (en) Pyridine salts and process
JP6508796B2 (ja) 新規なキナーゼ阻害剤の調製と使用
KR102690225B1 (ko) 퀴놀린 함유 화합물, 의약 조성물 및 그의 용도
JP2025514382A (ja) Ｒｏｃｋ２の阻害剤
KR20250009417A (ko) 혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도
An et al. The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer
EA015103B1 (ru) Производные n-фенил-2-пиримидинамина и способ их получения
KR20250023339A (ko) 페닐 트라이아졸 mll1-wdr5 단백질-단백질 상호작용 저해제
US9738613B2 (en) Substituted 1,2,3-triazoles as antitumor agents
WO2022217010A1 (en) Compounds and methods for the targeted degradation of estrogen receptors
EP3176160A1 (en) Pyridine-substituted 2-aminopyridine protein kinase inhibitors
EP3418277A1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
EP3296294B1 (en) Compound for treating or preventing breast cancer
JP2020517654A (ja) ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法
US20230095530A1 (en) Compound used as ret kinase inhibitor and application thereof
KR20250097910A (ko) 포스파티딜이노시톨 3-키나제의 신규 억제제
CN121443598A (zh) 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
HK40108829A (zh) Shp2抑制剂单一疗法及其用途
WO2017164173A1 (ja) イミダゾール化合物及びこれを含有する医薬
HK1191936A (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000